{"id":23468,"date":"2025-07-06T06:05:42","date_gmt":"2025-07-06T06:05:42","guid":{"rendered":"https:\/\/youzum.net\/chai-discovery-team-releases-chai-2-ai-model-achieves-16-hit-rate-in-de-novo-antibody-design\/"},"modified":"2025-07-06T06:05:42","modified_gmt":"2025-07-06T06:05:42","slug":"chai-discovery-team-releases-chai-2-ai-model-achieves-16-hit-rate-in-de-novo-antibody-design","status":"publish","type":"post","link":"https:\/\/youzum.net\/it\/chai-discovery-team-releases-chai-2-ai-model-achieves-16-hit-rate-in-de-novo-antibody-design\/","title":{"rendered":"Chai Discovery Team Releases Chai-2: AI Model Achieves 16% Hit Rate in De Novo Antibody Design"},"content":{"rendered":"
TLDR:<\/strong> Chai Discovery Team introduces Chai-2, a multimodal AI model that enables zero-shot de novo antibody design. Achieving a 16% hit rate across 52 novel targets using \u226420 candidates per target, Chai-2 outperforms prior methods by over 100x and delivers validated binders in under two weeks\u2014eliminating the need for large-scale screening.<\/pre>\n
In a significant advancement for computational drug discovery, the Chai Discovery Team has introduced Chai-2<\/strong>, a multimodal generative AI platform capable of zero-shot antibody and protein binder design. Unlike previous approaches that rely on extensive high-throughput screening, Chai-2 reliably designs functional binders in a single 24-well plate<\/strong> setup, achieving more than 100-fold improvement<\/strong> over existing state-of-the-art (SOTA) methods.<\/p>\n
Chai-2 was tested on 52 novel targets<\/strong>, none of which had known antibody or nanobody binders in the Protein Data Bank (PDB). Despite this challenge, the system achieved a 16% experimental hit rate<\/strong>, discovering binders for 50% of the tested targets within a two-week cycle<\/strong> from computational design to wet-lab validation. This performance marks a shift from probabilistic screening to deterministic generation in molecular engineering.<\/p>\n
\n
\"\"<\/figure>\n<\/div>\n
AI-Powered De Novo Design at Experimental Scale<\/strong><\/h3>\n
Chai-2 integrates an all-atom generative design module<\/strong> and a folding model that predicts antibody-antigen complex structures with double the accuracy of its predecessor, Chai-1. The system operates in a zero-shot setting<\/strong>, generating sequences for antibody modalities like scFvs and VHHs without requiring prior binders.<\/p>\n
Key features of Chai-2 include:<\/strong><\/p>\n